{"organizations": [], "uuid": "445b4be447d7cc5c975750f922a9ee00a01cbfce", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/evolus-fda/update-1-fda-declines-to-approve-evolus-incs-rival-treatment-to-botox-idUSL3N1SN4WD", "country": "US", "domain_rank": 408, "title": "UPDATE 1-FDA declines to approve Evolus Inc's rival treatment to Botox", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-16T16:08:00.000+03:00", "replies_count": 0, "uuid": "445b4be447d7cc5c975750f922a9ee00a01cbfce"}, "author": "", "url": "https://www.reuters.com/article/evolus-fda/update-1-fda-declines-to-approve-evolus-incs-rival-treatment-to-botox-idUSL3N1SN4WD", "ord_in_thread": 0, "title": "UPDATE 1-FDA declines to approve Evolus Inc's rival treatment to Botox", "locations": [], "entities": {"persons": [{"name": "cantor fitzgerald", "sentiment": "none"}, {"name": "louise chen", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "evolus inc", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "botox reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16, 2018 / 1:11 PM / Updated 8 minutes ago UPDATE 1-FDA declines to approve Evolus Inc's rival treatment to Botox Reuters Staff 2 Min Read\n(Adds details, background, shares)\nMay 16 (Reuters) - U.S. health regulators on Wednesday declined to approve Evolus Inc’s rival product to Allergan Plc’s Botox, citing certain deficiencies related to its potential treatment for frown lines.\nEvolus’ shares were down 22 percent at $11.50 in premarket trading.\nDWP-450 is the company’s potential treatment of glabellar lines, also known as frown lines, in adult patients.\nThe deficiencies cited by the U.S. Food and Drug Administration were isolated to items related to chemistry, manufacturing, and controls processes, the company said.\nThe FDA’s decision was widely anticipated, after it had issued a “form 483”, which outlined violations at the company’s facilities following inspections in 2017.\nFDA rejection of the application was likely, and an expected approval for the treatment could come by late summer, Cantor Fitzgerald analyst Louise Chen said in a note on Monday.\nThe company said that its partner Daewoong Pharmaceutical Co received a favorable inspection report of its manufacturing facility.\nA likely delay in the commercial launch of the product would be a positive for Allergan, which is expected to face competition from other products, including a biosimilar from Revance Therapeutics. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)", "external_links": [], "published": "2018-05-16T16:08:00.000+03:00", "crawled": "2018-05-16T16:22:10.000+03:00", "highlightTitle": ""}